Estrella Immunopharma, Inc. (ESLA)
0.39
-0.02
(-4.90%)
USD |
NASDAQ |
Nov 06, 10:26
Estrella Immunopharma Net Income (Quarterly) : -2.306M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -2.306M |
| March 31, 2026 | -2.292M |
| December 31, 2025 | -0.6132M |
| September 30, 2025 | -4.801M |
| June 30, 2025 | -5.545M |
| March 31, 2025 | -2.104M |
| December 31, 2024 | -1.050M |
| September 30, 2024 | -3.377M |
| June 30, 2024 | -3.951M |
| March 31, 2024 | -0.4695M |
| December 31, 2023 | -1.021M |
| Date | Value |
|---|---|
| September 30, 2023 | -1.870M |
| June 30, 2023 | -0.076M |
| March 31, 2023 | -0.0633M |
| December 31, 2022 | -0.1504M |
| September 30, 2022 | -0.3449M |
| June 30, 2022 | -0.3596M |
| March 31, 2022 | -0.1413M |
| December 31, 2021 | -0.1358M |
| September 30, 2021 | -0.1075M |
| June 30, 2021 | -0.0036M |
| February 28, 2021 | -0.0008M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 53.52M |
| Alnylam Pharmaceuticals, Inc. | 2.167B |
| Anika Therapeutics, Inc. | 3.309M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 2.306M |
| EPS Diluted (Quarterly) | -0.0536 |
| Enterprise Value | 17.50M |
| Earnings Yield | -65.03% |
| Normalized Earnings Yield | -63.64 |